Connection

JEFFREY ROSEN to Humans

This is a "connection" page, showing publications JEFFREY ROSEN has written about Humans.
Connection Strength

0.796
  1. CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer. JCI Insight. 2024 Sep 17; 9(20).
    View in: PubMed
    Score: 0.026
  2. Leveraging preclinical models of metastatic breast cancer. Biochim Biophys Acta Rev Cancer. 2024 09; 1879(5):189163.
    View in: PubMed
    Score: 0.026
  3. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. J Clin Invest. 2023 12 15; 133(24).
    View in: PubMed
    Score: 0.025
  4. Targeted Inhibition of lncRNA Malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative Breast Cancer. Cancer Immunol Res. 2023 11 01; 11(11):1462-1479.
    View in: PubMed
    Score: 0.025
  5. Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer. Cancer Res. 2022 06 15; 82(12):2281-2297.
    View in: PubMed
    Score: 0.022
  6. Single-Cell Analysis Unveils the Role of the Tumor Immune Microenvironment and Notch Signaling in Dormant Minimal Residual Disease. Cancer Res. 2022 Mar 01; 82(5):885-899.
    View in: PubMed
    Score: 0.022
  7. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Res Commun. 2021 12; 1(3):178-193.
    View in: PubMed
    Score: 0.022
  8. Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies. Semin Cancer Biol. 2022 07; 82:3-10.
    View in: PubMed
    Score: 0.021
  9. TIME Is a Great Healer-Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes. Cells. 2020 12 23; 10(1).
    View in: PubMed
    Score: 0.020
  10. New twists on long noncoding RNAs: from mobile elements to motile cancer cells. RNA Biol. 2020 11; 17(11):1535-1549.
    View in: PubMed
    Score: 0.019
  11. C/EBP? Isoform Specific Gene Regulation: It's a Lot more Complicated than you Think! J Mammary Gland Biol Neoplasia. 2020 03; 25(1):1-12.
    View in: PubMed
    Score: 0.019
  12. Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression. Oncogene. 2017 10 26; 36(43):5958-5968.
    View in: PubMed
    Score: 0.016
  13. The Cellular Origin and Evolution of Breast Cancer. Cold Spring Harb Perspect Med. 2017 Mar 01; 7(3).
    View in: PubMed
    Score: 0.016
  14. Repurposing Antiestrogens for Tumor Immunotherapy. Cancer Discov. 2017 01; 7(1):17-19.
    View in: PubMed
    Score: 0.015
  15. The mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapes. Endocr Relat Cancer. 2015 Dec; 22(6):T161-76.
    View in: PubMed
    Score: 0.014
  16. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene. 2015 Dec 03; 34(49):5997-6006.
    View in: PubMed
    Score: 0.014
  17. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015 May; 5(5):520-33.
    View in: PubMed
    Score: 0.014
  18. Regulation of mammary epithelial cell homeostasis by lncRNAs. Int J Biochem Cell Biol. 2014 Sep; 54:318-30.
    View in: PubMed
    Score: 0.013
  19. Paracrine signaling in mammary gland development: what can we learn about intratumoral heterogeneity? Breast Cancer Res. 2014 Jan 29; 16(1):202.
    View in: PubMed
    Score: 0.013
  20. Noncoding RNAs involved in mammary gland development and tumorigenesis: there's a long way to go. J Mammary Gland Biol Neoplasia. 2012 Mar; 17(1):43-58.
    View in: PubMed
    Score: 0.011
  21. Mammary gland development & breast cancer; connecting the dots by non-coding RNAs. J Mammary Gland Biol Neoplasia. 2012 Mar; 17(1):1-2.
    View in: PubMed
    Score: 0.011
  22. On hormone action in the mammary gland. Cold Spring Harb Perspect Biol. 2012 Feb 01; 4(2).
    View in: PubMed
    Score: 0.011
  23. Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model. Cancer Biol Ther. 2011 Aug 15; 12(4):278-87.
    View in: PubMed
    Score: 0.011
  24. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2778-83.
    View in: PubMed
    Score: 0.010
  25. Wnt and mammary stem cells: hormones cannot fly wingless. Curr Opin Pharmacol. 2010 Dec; 10(6):643-9.
    View in: PubMed
    Score: 0.010
  26. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med. 2010 Oct 27; 2(55):55ra79.
    View in: PubMed
    Score: 0.010
  27. Small players with big roles: microRNAs as targets to inhibit breast cancer progression. Curr Drug Targets. 2010 Sep; 11(9):1059-73.
    View in: PubMed
    Score: 0.010
  28. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res. 2010 Jun 15; 70(12):4868-79.
    View in: PubMed
    Score: 0.010
  29. The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol. 2010 May-Jun; 7(3):300-4.
    View in: PubMed
    Score: 0.010
  30. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010 Jun; 15(2):253-60.
    View in: PubMed
    Score: 0.010
  31. Chk1 haploinsufficiency results in anemia and defective erythropoiesis. PLoS One. 2010 Jan 05; 5(1):e8581.
    View in: PubMed
    Score: 0.009
  32. Chking and executing cell division to prevent genomic instability. Cell Cycle. 2009 Aug; 8(15):2339-42.
    View in: PubMed
    Score: 0.009
  33. The increasing complexity of the cancer stem cell paradigm. Science. 2009 Jun 26; 324(5935):1670-3.
    View in: PubMed
    Score: 0.009
  34. Lactogenic hormonal induction of long distance interactions between beta-casein gene regulatory elements. J Biol Chem. 2009 Aug 21; 284(34):22815-24.
    View in: PubMed
    Score: 0.009
  35. Minireview: hormones and mammary cell fate--what will I become when I grow up? Endocrinology. 2008 Sep; 149(9):4317-21.
    View in: PubMed
    Score: 0.008
  36. The C-terminal domain of the nuclear factor I-B2 isoform is glycosylated and transactivates the WAP gene in the JEG-3 cells. Biochem Biophys Res Commun. 2007 Jul 06; 358(3):770-6.
    View in: PubMed
    Score: 0.008
  37. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A. 2007 Jan 09; 104(2):618-23.
    View in: PubMed
    Score: 0.008
  38. Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Res. 2007; 9(4):304.
    View in: PubMed
    Score: 0.008
  39. P190-B Rho GTPase-activating protein overexpression disrupts ductal morphogenesis and induces hyperplastic lesions in the developing mammary gland. Mol Endocrinol. 2006 Jun; 20(6):1391-405.
    View in: PubMed
    Score: 0.007
  40. Stop! In the name of transforming growth factor-beta: keeping estrogen receptor-alpha-positive mammary epithelial cells from proliferating. Breast Cancer Res. 2006; 8(4):106.
    View in: PubMed
    Score: 0.007
  41. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev. 2006 Feb; 16(1):60-4.
    View in: PubMed
    Score: 0.007
  42. On mammary stem cells. J Cell Sci. 2005 Aug 15; 118(Pt 16):3585-94.
    View in: PubMed
    Score: 0.007
  43. Stem/progenitor cells in mouse mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2005 Jan; 10(1):17-24.
    View in: PubMed
    Score: 0.007
  44. Chk1 versus Cdc25: chking one's levels of cellular proliferation. Cell Cycle. 2004 Nov; 3(11):1355-7.
    View in: PubMed
    Score: 0.007
  45. IRE1a silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024 Dec 12; 187(25):7248-7266.e34.
    View in: PubMed
    Score: 0.007
  46. Will cancer stem cells provide new therapeutic targets? Carcinogenesis. 2005 Apr; 26(4):703-11.
    View in: PubMed
    Score: 0.007
  47. Multispecies comparative analysis of a mammalian-specific genomic domain encoding secretory proteins. Genomics. 2003 Oct; 82(4):417-32.
    View in: PubMed
    Score: 0.006
  48. Isolation and characterization of functional mammary gland stem cells. Cell Prolif. 2003 Oct; 36 Suppl 1:17-32.
    View in: PubMed
    Score: 0.006
  49. Striking it rich by data mining. Cell. 2003 Aug 08; 114(3):271-2.
    View in: PubMed
    Score: 0.006
  50. Transcription factors. J Mammary Gland Biol Neoplasia. 2003 Apr; 8(2):143-4.
    View in: PubMed
    Score: 0.006
  51. The role of C/EBPbeta in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2003 Apr; 8(2):191-204.
    View in: PubMed
    Score: 0.006
  52. Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b. J Biol Chem. 2003 May 09; 278(19):17218-27.
    View in: PubMed
    Score: 0.006
  53. LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells. Cancer Immunol Res. 2023 02 03; 11(2):171-183.
    View in: PubMed
    Score: 0.006
  54. The tumor-immune ecosystem in shaping metastasis. Am J Physiol Cell Physiol. 2023 03 01; 324(3):C707-C717.
    View in: PubMed
    Score: 0.006
  55. Mechanisms of cancer metastasis. Semin Cancer Biol. 2022 12; 87:17-31.
    View in: PubMed
    Score: 0.006
  56. STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022 11; 41(48):5214-5222.
    View in: PubMed
    Score: 0.006
  57. Noncanonical Wnt/Ror2 signaling regulates cell-matrix adhesion to prompt directional tumor cell invasion in breast cancer. Mol Biol Cell. 2022 09 15; 33(11):ar103.
    View in: PubMed
    Score: 0.006
  58. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med. 2021 Oct 27; 13(617):eabe6201.
    View in: PubMed
    Score: 0.005
  59. CD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer. 2021 07; 125(2):176-189.
    View in: PubMed
    Score: 0.005
  60. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021 01 21; 184(2):384-403.e21.
    View in: PubMed
    Score: 0.005
  61. Protein quality control through endoplasmic reticulum-associated degradation maintains haematopoietic stem cell identity and niche interactions. Nat Cell Biol. 2020 10; 22(10):1162-1169.
    View in: PubMed
    Score: 0.005
  62. Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer. J Vis Exp. 2020 05 18; (159).
    View in: PubMed
    Score: 0.005
  63. The SINEB1 element in the long non-coding RNA Malat1 is necessary for TDP-43 proteostasis. Nucleic Acids Res. 2020 03 18; 48(5):2621-2642.
    View in: PubMed
    Score: 0.005
  64. Metastasis Organotropism: Redefining the Congenial Soil. Dev Cell. 2019 05 06; 49(3):375-391.
    View in: PubMed
    Score: 0.005
  65. GSK3? regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. Breast Cancer Res. 2019 03 07; 21(1):37.
    View in: PubMed
    Score: 0.004
  66. Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest. 2018 04 02; 128(4):1283-1299.
    View in: PubMed
    Score: 0.004
  67. Composite response elements mediate hormonal and developmental regulation of milk protein gene expression. Biochem Soc Symp. 1998; 63:101-13.
    View in: PubMed
    Score: 0.004
  68. Genome-wide identification and differential analysis of translational initiation. Nat Commun. 2017 11 23; 8(1):1749.
    View in: PubMed
    Score: 0.004
  69. TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway. Oncogene. 2017 04 27; 36(17):2377-2393.
    View in: PubMed
    Score: 0.004
  70. Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol. 2016 06; 18(6):632-44.
    View in: PubMed
    Score: 0.004
  71. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers. Dis Model Mech. 2016 07 01; 9(7):749-57.
    View in: PubMed
    Score: 0.004
  72. The mammary gland as a bioreactor: factors regulating the efficient expression of milk protein-based transgenes. Am J Clin Nutr. 1996 Apr; 63(4):627S-32S.
    View in: PubMed
    Score: 0.004
  73. Engineering transgenes for use in the mammary gland. Genet Eng (N Y). 1996; 18:57-81.
    View in: PubMed
    Score: 0.004
  74. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Res Treat. 2015 Jul; 152(2):347-56.
    View in: PubMed
    Score: 0.003
  75. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015 Feb 09; 27(2):193-210.
    View in: PubMed
    Score: 0.003
  76. The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.
    View in: PubMed
    Score: 0.003
  77. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 2014 Oct; 32(10):2571-82.
    View in: PubMed
    Score: 0.003
  78. Wnt-responsive cancer stem cells are located close to distorted blood vessels and not in hypoxic regions in a p53-null mouse model of human breast cancer. Stem Cells Transl Med. 2014 Jul; 3(7):857-66.
    View in: PubMed
    Score: 0.003
  79. The regulation of mammary gland development by hormones, growth factors, and oncogenes. Prog Clin Biol Res. 1994; 387:95-111.
    View in: PubMed
    Score: 0.003
  80. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 2013 Nov 12; 14(11):R125.
    View in: PubMed
    Score: 0.003
  81. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res. 2013 Sep 01; 19(17):4889-99.
    View in: PubMed
    Score: 0.003
  82. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res. 2013 Mar 15; 73(6):1981-92.
    View in: PubMed
    Score: 0.003
  83. Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci Rep. 2013; 3:2687.
    View in: PubMed
    Score: 0.003
  84. Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis. PLoS One. 2012; 7(1):e30814.
    View in: PubMed
    Score: 0.003
  85. Progesterone receptor directly inhibits ?-casein gene transcription in mammary epithelial cells through promoting promoter and enhancer repressive chromatin modifications. Mol Endocrinol. 2011 Jun; 25(6):955-68.
    View in: PubMed
    Score: 0.003
  86. The DNA damage effector Chk1 kinase regulates Cdc14B nucleolar shuttling during cell cycle progression. Cell Cycle. 2011 Feb 15; 10(4):671-9.
    View in: PubMed
    Score: 0.003
  87. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70.
    View in: PubMed
    Score: 0.003
  88. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010 Aug 31; 107(35):15449-54.
    View in: PubMed
    Score: 0.002
  89. The epigenetic landscape of mammary gland development and functional differentiation. J Mammary Gland Biol Neoplasia. 2010 Mar; 15(1):85-100.
    View in: PubMed
    Score: 0.002
  90. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5.
    View in: PubMed
    Score: 0.002
  91. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res. 2009 Mar 15; 69(6):2244-51.
    View in: PubMed
    Score: 0.002
  92. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009; 11(5):R66.
    View in: PubMed
    Score: 0.002
  93. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.
    View in: PubMed
    Score: 0.002
  94. Progesterone receptor repression of prolactin/signal transducer and activator of transcription 5-mediated transcription of the beta-casein gene in mammary epithelial cells. Mol Endocrinol. 2007 Jan; 21(1):106-25.
    View in: PubMed
    Score: 0.002
  95. Maspin is physically associated with [beta]1 integrin regulating cell adhesion in mammary epithelial cells. FASEB J. 2006 Jul; 20(9):1510-2.
    View in: PubMed
    Score: 0.002
  96. The dynamic mobility of histone H1 is regulated by cyclin/CDK phosphorylation. Mol Cell Biol. 2003 Dec; 23(23):8626-36.
    View in: PubMed
    Score: 0.002
  97. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. Mol Cancer Res. 2003 Dec; 1(14):1036-47.
    View in: PubMed
    Score: 0.002
  98. Rat beta casein cDNA: sequence analysis and evolutionary comparisons. Nucleic Acids Res. 1982 Apr 10; 10(7):2295-307.
    View in: PubMed
    Score: 0.001
  99. Mechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci. 2001 Dec; 952:23-35.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.